» Articles » PMID: 23997525

Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Leukemia

Overview
Specialty Oncology
Date 2013 Sep 3
PMID 23997525
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The purposes of this study were to assess the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia (AL) and analyze the factors affecting the prognosis of these patients.

Methods: The clinical and follow-up data of 93 AL patients (median age, 30 years) undergoing allogeneic HSCT in Xiangya Hospital over the past 12 years were collected, and the potential factors affecting the efficacy and prognosis of allogeneic HSCT patients were determined.

Results: Hematopoietic reconstitution was achieved in 90 patients. At the last follow-up, the incidences of severe acute graft versus host disease (aGvHD) and extensive chronic GvHD (cGvHD) were 14.0% and 20.0%, the 3-year cumulative incidence of transplantation related mortality (TRM) and relapse rate were 16.8%±6.1% and 21.3%±6.7%, and the estimated 3-year overall survival (OS) and disease-free survival (DFS) of the patients were 64.6%±5.4% and 56.5%±5.5%, respectively. Univariate analysis indicated that age older than 40 years, HLA mismatch, and severe lung infection within the first 100 days after transplantation were risk factors for severe aGvHD, age older than 40 years, HLA mismatch, severe lung infection within the first 100 days after transplantation, and severe aGvHD were risk factors for TRM, high-risk AL and lack of cGvHD were risk factors for relapse (all P<0.05). Survival estimation showed that HLA mismatch, severe lung infection occurring within the first 100 days post-transplantation, high-risk AL severe aGvHD and lack of cGvHD were risk factors associated with poor prognosis (all P<0.05). Further multivariate analyses revealed that severe lung infection within the first 100 days post-transplantation, severe aGvHD and lack of cGvHD were independent risk factors for unfavorable outcomes (all P<0.05).

Conclusions: Allogeneic HSCT can improve the DFS of AL patients, and severe lung infection within the first 100 days post-transplantation, severe aGvHD and lack of cGvHD are independent risk factors affecting the prognosis.

Citing Articles

The absence of AhR in CD4 T cells in patients with acute graft-versus-host disease may be related to insufficient CTCF expression.

Zeng C, Cheng T, Ma X, Liu Y, Hua J, Chen X Clin Epigenetics. 2022; 14(1):109.

PMID: 36056390 PMC: 9440523. DOI: 10.1186/s13148-022-01330-7.


Proliferation kinetics of immune cells during early phase of bone marrow transplantation in mouse model based on chemotherapy conditioning.

Chen C, DA Z, Lu Y, Zhou J, Li X, Fu B Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021; 46(5):449-457.

PMID: 34148880 PMC: 10930221. DOI: 10.11817/j.issn.1672-7347.2021.190496.


Downregulation of p53 by Insufficient CTCF in CD4 T Cells Is an Important Factor Inducing Acute Graft-Versus-Host Disease.

Hua J, Chen Y, Fu B, Chen X, Xu X, Yang S Front Immunol. 2020; 11:568637.

PMID: 33133081 PMC: 7550539. DOI: 10.3389/fimmu.2020.568637.


HMGB1 Recruits TET2/AID/TDG to Induce DNA Demethylation in STAT3 Promoter in CD4 T Cells from aGVHD Patients.

Xu X, Chen Y, Liu E, Fu B, Hua J, Chen X J Immunol Res. 2020; 2020:7165230.

PMID: 33029541 PMC: 7532413. DOI: 10.1155/2020/7165230.


A Possible Reason to Induce Acute Graft-vs.-Host Disease After Hematopoietic Stem Cell Transplantation: Lack of Sirtuin-1 in CD4 T Cells.

Xu Y, Chen F, Chen Y, Fu B, Liu E, Zou L Front Immunol. 2019; 9:3078.

PMID: 30622543 PMC: 6308326. DOI: 10.3389/fimmu.2018.03078.


References
1.
Sellar R, Peggs K . Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation. Future Oncol. 2012; 8(12):1549-65. DOI: 10.2217/fon.12.153. View

2.
Platzbecker U . Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes. Semin Hematol. 2012; 49(4):342-9. DOI: 10.1053/j.seminhematol.2012.07.003. View

3.
Ishiyama K, Takami A, Kanda Y, Nakao S, Hidaka M, Maeda T . Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis. Leukemia. 2011; 26(3):461-4. DOI: 10.1038/leu.2011.229. View

4.
Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

5.
Advani A, Hunger S, Burnett A . Acute leukemia in adolescents and young adults. Semin Oncol. 2009; 36(3):213-26. DOI: 10.1053/j.seminoncol.2009.03.007. View